Merck Mevacor Pediatric Exclusivity Gets July 3 Hearing; 5 Generics Stayed
Executive SummaryThe D.C. federal court is scheduled to hear arguments on Merck's Mevacor pediatric exclusivity application July 3.
You may also be interested in...
Amgen asserts FDA improperly tied pediatric exclusivity denial to lack of meaningful labeling resulting from the studies; justices question whether Amgen's data were adequate to support exclusivity but also agency's public silence on how it decides when a sponsor has 'fairly responded' to a written request.
In suit against FDA, Amgen argues it provided sufficient data to obtain exclusivity for Sensipar but agency says too few patients were included in one study; court ruled against FDA in similar 2001 dispute.